203 related articles for article (PubMed ID: 30229572)
1. Recent Topics in Fibrodysplasia Ossificans Progressiva.
Katagiri T; Tsukamoto S; Nakachi Y; Kuratani M
Endocrinol Metab (Seoul); 2018 Sep; 33(3):331-338. PubMed ID: 30229572
[TBL] [Abstract][Full Text] [Related]
2. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
Katagiri T; Tsukamoto S; Kuratani M
Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in drug development for fibrodysplasia ossificans progressiva.
Meng X; Wang H; Hao J
Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530
[TBL] [Abstract][Full Text] [Related]
4. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
5. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
Sánchez-Duffhues G; Williams E; Benderitter P; Orlova V; van Wijhe M; Garcia de Vinuesa A; Kerr G; Caradec J; Lodder K; de Boer HC; Goumans MJ; Eekhoff EMW; Morales-Piga A; Bachiller-Corral J; Koolwijk P; Bullock AN; Hoflack J; Ten Dijke P
JBMR Plus; 2019 Nov; 3(11):e10230. PubMed ID: 31768489
[TBL] [Abstract][Full Text] [Related]
6. Drosophila models of FOP provide mechanistic insight.
Le V; Anderson E; Akiyama T; Wharton KA
Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
[TBL] [Abstract][Full Text] [Related]
7. Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Luo Y; Alsamarah A; Zhang K; Hao J
Curr Mol Med; 2016; 16(1):4-11. PubMed ID: 26695699
[TBL] [Abstract][Full Text] [Related]
8. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
9. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
Takahashi M; Katagiri T; Furuya H; Hohjoh H
Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
[TBL] [Abstract][Full Text] [Related]
10. Periodontal ligament fibroblasts as a cell model to study osteogenesis and osteoclastogenesis in fibrodysplasia ossificans progressiva.
de Vries TJ; Schoenmaker T; Micha D; Hogervorst J; Bouskla S; Forouzanfar T; Pals G; Netelenbos C; Eekhoff EMW; Bravenboer N
Bone; 2018 Apr; 109():168-177. PubMed ID: 28705683
[TBL] [Abstract][Full Text] [Related]
11. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
[TBL] [Abstract][Full Text] [Related]
12. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
[TBL] [Abstract][Full Text] [Related]
14. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
[TBL] [Abstract][Full Text] [Related]
15. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
[TBL] [Abstract][Full Text] [Related]
16. Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva.
Ventura F; Williams E; Ikeya M; Bullock AN; Ten Dijke P; Goumans MJ; Sanchez-Duffhues G
Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33669809
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel 2-aminopyrazine-3-carboxamide as a potent and selective inhibitor of Activin Receptor-Like Kinase-2 (ALK2) for the treatment of fibrodysplasia ossificans progressiva.
Ullrich T; Arista L; Weiler S; Teixeira-Fouchard S; Broennimann V; Stiefl N; Head V; Kramer I; Guth S
Bioorg Med Chem Lett; 2022 May; 64():128667. PubMed ID: 35276359
[TBL] [Abstract][Full Text] [Related]
18. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
[TBL] [Abstract][Full Text] [Related]
19. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.
Towler OW; Shore EM; Xu M; Bamford A; Anderson I; Pignolo RJ; Kaplan FS
Eur J Med Genet; 2017 Jul; 60(7):399-402. PubMed ID: 28473268
[TBL] [Abstract][Full Text] [Related]
20. When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).
Kaplan FS; Groppe J; Shore EM
Drug Discov Today Ther Strateg; 2008; 5(4):255-262. PubMed ID: 23599718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
